common.study.topics.clinical

Open-Label Extension and Safety Study of Talazoparib

common.study.values.description

“Open-Label Extension and Safety Study of Talazoparib”

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Talazoparib

Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol

participant.views.study.view.additional

participant.views.study.view.scientific-title

A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB

common.study.values.clinical-trial-id

NCT02921919

participant.views.study.view.id

9aA7ld